<table cellpadding="0pt" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="18%"></col>
<col width="82%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="middle">
<paragraph>
<content stylecode="bold">Moderate to Strong CYP3A4 Inhibitors</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Significantly increased exposure of aprepitant may increase the risk of adverse reactions associated with aprepitant [see <content stylecode="bold">ADVERSE REACTIONS (<linkhtml href="#i4i_section_id_2ef8f727-0eca-4752-9583-8499b489804e">6.1</linkhtml>)</content> and <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Avoid concomitant use of aprepitant</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Examples</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="underline">Moderate inhibitor:</content>
</item>
<item>
<caption> </caption>diltiazem</item>
<item>
<caption> </caption>
<content stylecode="underline">Strong inhibitors:</content>
</item>
<item>
<caption> </caption>ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir</item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">Strong CYP3A4 Inducers</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Clinical Impact</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of aprepitant [see <content stylecode="bold">CLINICAL PHARMACOLOGY (<linkhtml href="#i4i_pharmacokinetics_id_374a5eb4-fe8d-4096-a4dd-d60afb1a4706">12.3</linkhtml>)</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Intervention</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>Avoid concomitant use of aprepitant</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="italics">Examples</content>
</item>
</list>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>rifampin, carbamazepine, phenytoin</item>
</list>
</td>
</tr>
</tbody>
</table>